Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.38) by 13.16 percent. This is a 186.67 percent decrease over losses of $(0.15) per
Monte Rosa lost more money per share than people expected, but their sales grew much bigger than forecast. When a company loses money but sells more, it hints they're investing heavily to grow—watch if losses shrink over time.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.